Noro-Moseley Partners
SEC exempt reporting adviser (venture capital exemption).
- HQ
- GA
Noro-Moseley Partners is an early growth equity firm focused on rapidly-scaling B2B technology and healthcare companies. Allen Moseley serves as Managing General Partner, supported by general partners, a principal, and other team members. Portfolio companies named in the facts include Trilliant Health, Brinqa, EAIGLE, Rialtic, Medix Infusion, Avo, Visana Health, Red Canary, and Datasembly.
01 · Says / Does
| Tag | Says | Does | Historically (to 2020) |
|---|---|---|---|
| Stages | Not stated | Not enough dated deals | Series B, Growth, Series A |
| Sectors | Cybersecurity, Enterprise SaaS, Fintech, Healthtech | Not enough dated deals | Enterprise SaaS, Media, Healthtech, Cybersecurity, Hardware |
| Regions | US | Not enough dated deals | GA, NC, TX |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
Historical focus (through 2020), derived from historical deal data.
| Year | Deals | Top sectors |
|---|---|---|
| 1999 | 2 | Enterprise SaaS |
| 2000 | 10 | Hardware, Cybersecurity, AI applications |
| 2001 | 4 | Enterprise SaaS, Healthtech, Media |
| 2002 | 7 | Enterprise SaaS, Media, Biotech |
| 2003 | 3 | Media, Hardware, Manufacturing |
| 2004 | 8 | Hardware, Healthtech, Cybersecurity |
| 2005 | 3 | Biotech, Cybersecurity, Data analytics |
| 2006 | 7 | Manufacturing, Media, Cybersecurity |
| 2007 | 6 | Media, Cybersecurity, Data analytics |
| 2008 | 5 | Media, Data analytics, Edtech |
| 2009 | 3 | Enterprise SaaS, Cybersecurity, Hardware |
| 2010 | 6 | Media, Enterprise SaaS, Ecommerce |
| 2011 | 8 | Enterprise SaaS, Ecommerce, Data analytics |
| 2012 | 6 | Enterprise SaaS, Healthtech, Digital health |
| 2013 | 8 | Enterprise SaaS, Healthtech, HR and future of work |
| 2014 | 5 | Enterprise SaaS, Biotech, Cybersecurity |
| 2015 | 7 | Enterprise SaaS, Healthtech, Cybersecurity |
| 2016 | 6 | Enterprise SaaS, Healthtech, Media |
| 2017 | 2 | Enterprise SaaS, Healthtech |
| 2018 | 6 | Healthtech, Enterprise SaaS, Biotech |
| 2019 | 5 | Enterprise SaaS, Biotech, Cybersecurity |
Stage mix over time
- Pre-seed
- Seed
- Series A
- Series B
- Growth
| Year | Pre-seed | Seed | Series A | Series B | Growth |
|---|---|---|---|---|---|
| 2010 | 0 | 0 | 3 | 2 | 0 |
| 2011 | 0 | 0 | 3 | 2 | 0 |
| 2012 | 0 | 0 | 2 | 3 | 0 |
| 2013 | 0 | 1 | 0 | 1 | 4 |
| 2014 | 0 | 0 | 2 | 2 | 1 |
| 2015 | 0 | 0 | 0 | 2 | 3 |
| 2016 | 0 | 0 | 1 | 2 | 2 |
| 2017 | 0 | 0 | 0 | 1 | 1 |
| 2018 | 0 | 0 | 2 | 2 | 2 |
| 2019 | 0 | 0 | 2 | 0 | 2 |
| 2020 | 0 | 0 | 0 | 0 | 0 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 |
| 2026 | 0 | 0 | 0 | 0 | 0 |
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| Noro-Moseley Partners IX-B, L.P. | approx. 2023 | Not reported | Open, writing first checks |
| Noro-Moseley Partners IX, L.P. Noro-Moseley Partners makes early growth equity investments in rapidly scaling B2B technology and healthcare companies. It looks for year-over-year growth of 50%+, compelling unit economics, and significant opportunities for market disruption, typically among companies with minimal prior funding. Inferred from the firm's website | 2022 | $153.77M to $167.85M (Form D and SEC adviser filing) | Open, writing first checks |
03 · People across funds
- Alan Taetle, A controlling member of the General Partner.
Noro-Moseley Partners IX-B, L.P. (Named on Form D); Noro-Moseley Partners IX, L.P. (Named on Form D)
- Allen Moseley, A controlling member of the General Partner.
Noro-Moseley Partners IX-B, L.P. (Named on Form D); Noro-Moseley Partners IX, L.P. (Named on Form D)
- John Ale, Jr., A controlling member of the General Partner.
Noro-Moseley Partners IX-B, L.P. (Named on Form D); Noro-Moseley Partners IX, L.P. (Named on Form D)
- W. McClelland, A controlling member of the General Partner.
Noro-Moseley Partners IX-B, L.P. (Named on Form D); Noro-Moseley Partners IX, L.P. (Named on Form D)
- William Hudson, A controlling member of the General Partner.
Noro-Moseley Partners IX-B, L.P. (Named on Form D); Noro-Moseley Partners IX, L.P. (Named on Form D)
- Bill Hudson, Administrative Partner, CFO
- Brandon Aponte, Associate
- Ryan Collins, Principal
- Spence McClelland, General Partner
- Thomas Collier, Senior Associate
- Vasant Kamath, General Partner
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- https://noromoseley.com/contact-us/
- https://noromoseley.com/team/
- https://noromoseley.com/news/
- https://noromoseley.com/
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026